At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
AGN-199201 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
In Brief
A Phase 2 clinical trial evaluating AGN-199201, AGN-190584, and 1 other intervention for Presbyopia. Completed, enrolled 65 participants across 1 site.
Detailed Summary
A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPresbyopia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionOct 2014
Study CompletionNov 2014
TodayJul 2026
First PostedJul 23, 2014
Enrollment StartJul 1, 2014
Primary CompletionOct 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.9 years ago
Interventions
AGN-199201drug
1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
AGN-190584drug
1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
AGN-199201 Vehicledrug
1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.